Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
- PMID: 17008692
- DOI: 10.1200/JCO.2005.04.4859
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
Abstract
Purpose: Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years.
Methods: We used the Surveillance, Epidemiologic, and End Results (SEER) database to determine the incidence of SCLC over the last 30 years. In addition, we sought to determine sex- and stage-based differences in the incidence and survival of SCLC among a proportion of reported cases of lung cancer over the last 30 years (1973 to 2002). Joinpoint analyses were applied to test the trends in annual percentage change for statistical significance.
Results: The proportion of SCLC (among all lung cancer histologic types) decreased from 17.26% in 1986 to 12.95% in 2002. Of all patients with SCLC, the proportion of women with SCLC increased from 28% in 1973% to 50% in 2002. A modest but statistically significant improvement in 2- and 5-year survival was noted among both limited-stage SCLC and extensive-stage SCLC cohorts during the study period.
Conclusion: Our analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years. Possible explanations for the decreasing incidence include the decrease in the percentage of smokers and the change to low-tar filter cigarettes. Despite trends toward modest improvement in survival, the outcome remains very poor.
Comment in
-
Changing face of small-cell lung cancer: real and artifact.J Clin Oncol. 2006 Oct 1;24(28):4526-7. doi: 10.1200/JCO.2006.07.3841. J Clin Oncol. 2006. PMID: 17008688 No abstract available.
Similar articles
-
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.Cancer. 2002 Oct 1;95(7):1528-38. doi: 10.1002/cncr.10841. Cancer. 2002. PMID: 12237922
-
Contemporary lung cancer trends among U.S. women.Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):582-5. doi: 10.1158/1055-9965.EPI-04-0554. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15767333
-
Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.J Clin Oncol. 2007 Dec 10;25(35):5570-7. doi: 10.1200/JCO.2007.12.5435. J Clin Oncol. 2007. PMID: 18065729
-
[Is there progress in the chemotherapy of small cell lung cancer?].Schweiz Med Wochenschr. 1999 Sep 18;129(37):1313-20. Schweiz Med Wochenschr. 1999. PMID: 10515004 Review. German.
-
Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.Arch Phys Med Rehabil. 2008 Apr;89(4):595-601. doi: 10.1016/j.apmr.2007.09.042. Arch Phys Med Rehabil. 2008. PMID: 18373987 Review.
Cited by
-
Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.JAMA Netw Open. 2022 Oct 3;5(10):e2237699. doi: 10.1001/jamanetworkopen.2022.37699. JAMA Netw Open. 2022. PMID: 36264573 Free PMC article.
-
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6. Cancer Discov. 2012. PMID: 22961666 Free PMC article.
-
Effect of cigarette smoking on quality of life in small cell lung cancer patients.Eur J Cancer. 2012 Jul;48(11):1593-601. doi: 10.1016/j.ejca.2011.12.002. Epub 2012 Jan 12. Eur J Cancer. 2012. PMID: 22244802 Free PMC article.
-
Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity.Int J Mol Sci. 2023 Dec 22;25(1):224. doi: 10.3390/ijms25010224. Int J Mol Sci. 2023. PMID: 38203395 Free PMC article. Review.
-
ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report.Exp Ther Med. 2022 Sep 2;24(5):650. doi: 10.3892/etm.2022.11587. eCollection 2022 Nov. Exp Ther Med. 2022. PMID: 36168410 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical